Literature DB >> 31023743

CAR-T efficacy: is conditioning the key?

Sattva S Neelapu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31023743     DOI： 10.1182/blood-2019-03-900928

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  24 in total

1.  Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Adam Goldman; Elad Maor; David Bomze; Jennifer E Liu; Joerg Herrmann; Joshua Fein; Richard M Steingart; Syed S Mahmood; Wendy L Schaffer; Miguel-Angel Perales; Roni Shouval
Journal:  J Am Coll Cardiol       Date:  2021-11-02       Impact factor: 24.094

2.  CAR T cells reach clinical milestone in prostate cancer.

Authors:  Nicholas P Tschernia; Scott M Norberg; James L Gulley
Journal:  Nat Med       Date:  2022-04       Impact factor: 87.241

Review 3.  CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Authors:  Mohamad Mohty; Jordan Gautier; Florent Malard; Mahmoud Aljurf; Ali Bazarbachi; Christian Chabannon; Mohamed A Kharfan-Dabaja; Bipin N Savani; He Huang; Saad Kenderian; Arnon Nagler; Miguel-Angel Perales
Journal:  Leukemia       Date:  2019-11-05       Impact factor: 11.528

Review 4.  Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.

Authors:  Hans-Georg Eichler; Francesco Pignatti; Brigitte Schwarzer-Daum; Ana Hidalgo-Simon; Irmgard Eichler; Peter Arlett; Anthony Humphreys; Spiros Vamvakas; Nikolai Brun; Guido Rasi
Journal:  Clin Pharmacol Ther       Date:  2020-11-12       Impact factor: 6.875

Review 5.  The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.

Authors:  Jianshu Wei; Yang Liu; Chunmeng Wang; Yajing Zhang; Chuan Tong; Guanghai Dai; Wei Wang; John E J Rasko; J Joseph Melenhorst; Wenbin Qian; Aibin Liang; Weidong Han
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

Review 6.  Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.

Authors:  Xiang Zhou; Leo Rasche; K Martin Kortüm; Sophia Danhof; Michael Hudecek; Hermann Einsele
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

Review 7.  The potential of CAR T cell therapy for prostate cancer.

Authors:  Philipp Wolf; Jamal Alzubi; Christian Gratzke; Toni Cathomen
Journal:  Nat Rev Urol       Date:  2021-07-08       Impact factor: 14.432

Review 8.  The role of small molecules in cell and gene therapy.

Authors:  Lewis L Brayshaw; Carlos Martinez-Fleites; Takis Athanasopoulos; Thomas Southgate; Laurent Jespers; Christopher Herring
Journal:  RSC Med Chem       Date:  2020-12-24

Review 9.  Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.

Authors:  Laura Bracci; Alessandra Fragale; Lucia Gabriele; Federica Moschella
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

10.  Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

Authors:  Runxia Gu; Fang Liu; Dehui Zou; Yingxi Xu; Yang Lu; Bingcheng Liu; Wei Liu; Xiaojuan Chen; Kaiqi Liu; Ye Guo; Xiaoyuan Gong; Rui Lv; Xia Chen; Chunlin Zhou; Mengjun Zhong; Huijun Wang; Hui Wei; Yingchang Mi; Lugui Qiu; Lulu Lv; Min Wang; Ying Wang; Xiaofan Zhu; Jianxiang Wang
Journal:  J Hematol Oncol       Date:  2020-09-07       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.